Virbac has launched Curacef Duo, a unique combination of antibiotic and NSAID offering an alternative approach to the treatment of bovine respiratory disease (BRD) caused by Mannhaemia haemolytica and Pasteurella multocida. Virbac has launched Curacef Duo, a unique combination of antibiotic and NSAID offering an alternative approach to the treatment of bovine respiratory disease (BRD) caused by Mannhaemia haemolytica and Pasteurella multocida

Containing ceftiofur (50mg/ml) and ketoprofen (150mg/ml), Curacef Duo is presented in a ready-to-use suspension for injection at a low volume dosage – 1 ml/50kg – which is identical to short-acting ceftiofur alone.

Virbac says that Curacef Duo’s combined action can help to minimise production losses in calves and offer a quick return to production for dairy cows affected by bacterial BRD. It can also improve welfare by targeting infection, inflammation and pain all at once, while its ease of use and simple dosing help to increase compliance. Curacef Duo offers a zero milk withdrawal period and an eight day withdrawal period in meat. 

Brigitte Goasduf MRCVS, Large Animal Product Manager at Virbac, said: "In creating the first 'two-in-one' combination of two tried and trusted actives, the antibiotic ceftiofur and NSAID ketoprofen, we are offering practitioners an alternative to the treatment of bacterial BRD.

"We believe that the benefits Curacef Duo offers in terms of efficacy, ease of use and action on inflammation and pain, will be valued by both practitioners and farmers."

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.